Literature DB >> 20016041

Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.

Pamela Lockyer1, Jonathan C Schisler, Cam Patterson, Monte S Willis.   

Abstract

The peroxisome proliferator-activated receptor (PPAR) transcription factors are nuclear receptors initially identified for their key role in regulating metabolic processes. Recent studies designed to identify the role of PPARalpha, -beta, and -gamma in vivo uncovered extrametabolic roles that may be less well known in the heart. In this review, we describe what is known about these extrametabolic roles of PPARs, including regulation of cardiac inflammation, extracellular matrix remodeling, oxidative stress, and regulation of cardiac hypertrophy. Lastly, we discuss the emerging role of PPARs in cell cycle regulation and angiogenesis in noncardiac systems that may be applicable to heart biology. Although this review primarily discusses the extrametabolic role of PPARalpha, the most studied PPAR isoform in the heart, we highlight where possible what is known about the unique and overlapping roles of the PPAR isoforms in terms of metabolic function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016041      PMCID: PMC5417477          DOI: 10.1210/me.2009-0374

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  80 in total

Review 1.  Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.

Authors:  Victor J Dzau; Ruediger C Braun-Dullaeus; Daniel G Sedding
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

Review 2.  VEGF: an update on biological and therapeutic aspects.

Authors:  N Ferrara
Journal:  Curr Opin Biotechnol       Date:  2000-12       Impact factor: 9.740

Review 3.  Myocardial utilization of carbohydrate and lipids.

Authors:  J R Neely; M J Rovetto; J F Oram
Journal:  Prog Cardiovasc Dis       Date:  1972 Nov-Dec       Impact factor: 8.194

4.  Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.

Authors:  Madhankumar Rose; Pitchai Balakumar; Manjeet Singh
Journal:  Pharmacology       Date:  2007-06-15       Impact factor: 2.547

Review 5.  Status of cytokines in ischemia reperfusion induced heart injury.

Authors:  Ming Zhang; Li Chen
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2008-09

6.  Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.

Authors:  Tatsuhiko Shigeto; Yoshihito Yokoyama; Bing Xin; Hideki Mizunuma
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

7.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).

Authors:  G Torre-Amione; S Kapadia; C Benedict; H Oral; J B Young; D L Mann
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

Review 8.  PPAR dual agonists: are they opening Pandora's Box?

Authors:  Pitchai Balakumar; Madhankumar Rose; Subrahmanya S Ganti; Pawan Krishan; Manjeet Singh
Journal:  Pharmacol Res       Date:  2007-03-14       Impact factor: 7.658

9.  Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.

Authors:  Nathan K Lebrasseur; Toni-Ann S Duhaney; Deepa S De Silva; Lei Cui; Peter C Ip; Lija Joseph; Flora Sam
Journal:  Hypertension       Date:  2007-07-02       Impact factor: 10.190

10.  Mouse models to study angiogenesis in the context of cardiovascular diseases.

Authors:  Thierry Couffinhal; Pascale Dufourcq; Laurent Barandon; Lionel Leroux; Cecile Duplaa
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  10 in total

1.  PPARs, Cardiovascular Metabolism, and Function: Near- or Far-from-Equilibrium Pathways.

Authors:  Yves Lecarpentier; Victor Claes; Jean-Louis Hébert
Journal:  PPAR Res       Date:  2010-07-27       Impact factor: 4.964

2.  Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy.

Authors:  Eugenia Hovsepian; Federico Penas; Gerardo A Mirkin; Nora B Goren
Journal:  PPAR Res       Date:  2012-02-09       Impact factor: 4.964

Review 3.  Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction.

Authors:  Yves Lecarpentier; Victor Claes; Guillaume Duthoit; Jean-Louis Hébert
Journal:  Front Physiol       Date:  2014-11-04       Impact factor: 4.566

4.  Exposure to phthalates affects calcium handling and intercellular connectivity of human stem cell-derived cardiomyocytes.

Authors:  Nikki Gillum Posnack; Rabia Idrees; Hao Ding; Rafael Jaimes; Gulnaz Stybayeva; Zaruhi Karabekian; Michael A Laflamme; Narine Sarvazyan
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

5.  Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.

Authors:  Ágata C Cevey; Gerardo A Mirkin; Martín Donato; María J Rada; Federico N Penas; Ricardo J Gelpi; Nora B Goren
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-10-07       Impact factor: 4.077

6.  Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.

Authors:  Si-Chi Xu; Zhen-Guo Ma; Wen-Ying Wei; Yu-Pei Yuan; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2017-01-03       Impact factor: 4.964

7.  Fenofibrate Increases the Population of Non-Classical Monocytes in Asymptomatic Chagas Disease Patients and Modulates Inflammatory Cytokines in PBMC.

Authors:  Azul V Pieralisi; Ágata C Cevey; Federico N Penas; Nilda Prado; Ana Mori; Mónica Gili; Gerardo A Mirkin; Juan Gagliardi; Nora B Goren
Journal:  Front Cell Infect Microbiol       Date:  2022-03-11       Impact factor: 5.293

8.  Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors.

Authors:  Stéphane Mandard; David Patsouris
Journal:  PPAR Res       Date:  2013-03-07       Impact factor: 4.964

9.  MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet.

Authors:  Jun He; Megan T Quintana; Jenyth Sullivan; Traci L Parry; Trisha J Grevengoed; Jonathan C Schisler; Joseph A Hill; Cecelia C Yates; Rudo F Mapanga; M Faadiel Essop; William E Stansfield; James R Bain; Christopher B Newgard; Michael J Muehlbauer; Yipin Han; Brian A Clarke; Monte S Willis
Journal:  Cardiovasc Diabetol       Date:  2015-08-05       Impact factor: 9.951

Review 10.  Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.

Authors:  Wang-Soo Lee; Jaetaek Kim
Journal:  PPAR Res       Date:  2015-10-26       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.